NCT04958538 is a Phase 2 clinical trial of Methotrexate in Acute Graft Versus Host Disease, sponsored by Peking University People's Hospital.

Who is sponsoring NCT04958538?

NCT04958538 is sponsored by Peking University People's Hospital.

What drugs are being tested in NCT04958538?

Interventions in NCT04958538: Methotrexate.

What condition does NCT04958538 study?

NCT04958538 studies Acute Graft Versus Host Disease.

Is NCT04958538 still recruiting?

NCT04958538 is currently status unknown. Last updated 20 April 2022.

Last reviewed 2022-04-20 · How we verify

NCT04958538

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MTX and Steroid for III-IV aGVHD Treatment

Status unknown Phase 2 Last updated 20 April 2022

What this trial tests

Phase 2 trial testing Methotrexate in Acute Graft Versus Host Disease in 30 participants. Status unknown.

Timeline

21 April 2021

Primary endpoint
31 December 2022

30 January 2023

Quick facts

Lead sponsor	Peking University People's Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	21 April 2021
Primary completion	31 December 2022
Estimated completion	30 January 2023
Sites	1 location across China

Drugs / interventions tested

Methotrexate — full drug profile →

Conditions studied

Acute Graft Versus Host Disease — all drugs for Acute Graft Versus Host Disease →

Sponsor

Peking University People's Hospital

Who can join

Adults 15 to 65, any sex, with Acute Graft Versus Host Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to identify the efficacy and safety of methotrexate (MTX) combined corticosteroid treatment for grade III-IV acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Mini-dose methotrexate combined with methylprednisolone for the initial treatment of acute GVHD: a multicentre, randomized trial.
Wang Y, Liu QF, Wu DP, Xu ZL, et al · · 2024 · cited 11× · PMID 38664766 · DOI 10.1186/s12916-024-03395-y

Verify or expand the search:

Other trials of Methotrexate

Trials testing the same drug.

NCT07498465 — A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant · Phase 1 · withdrawn
NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
NCT07321912 — Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma · Phase 2 · not yet recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07477691 — Immune Modulation During Palynziq® Treatment in Adults (IMPALA) · Phase 4 · not yet recruiting

Other recruiting trials for Acute Graft Versus Host Disease

Currently open trials in the same condition.

NCT07285889 — First-Line Jaktinib for Acute Graft-Versus-Host Disease (aGVHD) · Phase 1, PHASE2 · recruiting
NCT07047456 — Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Post UCBT · Phase 3 · recruiting
NCT06904599 — Efficacy of Human Chorionic Gonadotropin in Acute GVHD Treatment · Phase 2 · recruiting
NCT06026371 — Fecal Microbiota Transplantation for the Prevention of Acute Graft Versus Host Disease in Adults Undergoing Allogeneic H · Phase 2 · active not recruiting
NCT05921305 — Mini-dose MTX Plus Standard-dose Steroid for the Initial Treatment of Acute GVHD · Phase 3 · recruiting

Other Peking University People's Hospital trials

Trials by the same sponsor.

NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04958538 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
Last refreshed: 20 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04958538.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing